首页 > 最新文献

Blood Cells Molecules and Diseases最新文献

英文 中文
Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies 出血诊断难题的表型和基因型评估:两个案例研究
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-10 DOI: 10.1016/j.bcmd.2024.102893
Sean X. Gu , Ayesha Butt , Vincent P. Schulz , Henry M. Rinder , Alfred I. Lee , Patrick G. Gallagher , John Hwa , Robert D. Bona

Inherited platelet disorders (IPDs) are a heterogeneous group of conditions that present significant challenges in diagnosis and management. Here, we report two cases of patients presenting with clinically significant bleeding but with unclear etiologies by conventional clinical laboratory testing. Further evaluation, utilizing a combination of high-dimensional multiplexed mass cytometry and genetic sequencing, revealed the underlying causes of bleeding in both cases, leading to definitive diagnoses. These cases underscore the potential utility of combined multimodal approaches in evaluating patients with bleeding disorders. Moreover, these high-parameter methods can offer substantial mechanistic insights and can enhance our understanding of the molecular pathogenesis of IPDs. Future studies involving larger patient cohorts are needed to further validate this strategy, directly comparing its diagnostic yield and accuracy with current clinical laboratory testing approaches, which can ultimately improve patient care.

遗传性血小板疾病(IPDs)是一类异质性疾病,给诊断和治疗带来了巨大挑战。在此,我们报告了两例临床出血症状明显但常规临床实验室检测病因不明的患者。通过结合使用高维多重质谱和基因测序技术进行进一步评估,发现了这两例患者出血的根本原因,并最终确诊。这些病例凸显了多模式联合方法在评估出血性疾病患者方面的潜在作用。此外,这些高参数方法还能提供实质性的机理见解,并能加深我们对 IPD 分子发病机制的了解。未来还需要对更大的患者群体进行研究,以进一步验证这一策略,将其诊断率和准确性与目前的临床实验室检测方法进行直接比较,从而最终改善患者护理。
{"title":"Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies","authors":"Sean X. Gu ,&nbsp;Ayesha Butt ,&nbsp;Vincent P. Schulz ,&nbsp;Henry M. Rinder ,&nbsp;Alfred I. Lee ,&nbsp;Patrick G. Gallagher ,&nbsp;John Hwa ,&nbsp;Robert D. Bona","doi":"10.1016/j.bcmd.2024.102893","DOIUrl":"10.1016/j.bcmd.2024.102893","url":null,"abstract":"<div><p>Inherited platelet disorders (IPDs) are a heterogeneous group of conditions that present significant challenges in diagnosis and management. Here, we report two cases of patients presenting with clinically significant bleeding but with unclear etiologies by conventional clinical laboratory testing. Further evaluation, utilizing a combination of high-dimensional multiplexed mass cytometry and genetic sequencing, revealed the underlying causes of bleeding in both cases, leading to definitive diagnoses. These cases underscore the potential utility of combined multimodal approaches in evaluating patients with bleeding disorders. Moreover, these high-parameter methods can offer substantial mechanistic insights and can enhance our understanding of the molecular pathogenesis of IPDs. Future studies involving larger patient cohorts are needed to further validate this strategy, directly comparing its diagnostic yield and accuracy with current clinical laboratory testing approaches, which can ultimately improve patient care.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"110 ","pages":"Article 102893"},"PeriodicalIF":2.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Outpatient ATG-free hematopoietic transplantation for severe aplastic anemia in limited-resource environments offers excellent results: Data from a single LATAM center” [Blood Cells, Mol. Dis. 109 (2024) 102885] 更正:"在资源有限的环境中,门诊无 ATG 造血移植治疗重型再生障碍性贫血效果极佳:来自一个拉美医学中心的数据" [Blood Cells, Mol. Dis. 109 (2024) 102885]。
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-06 DOI: 10.1016/j.bcmd.2024.102886
José Carlos Jaime-Pérez, Mariana González-Treviño, Andrés Gómez-De León, Miguel A. Campos-Bocardo, Renata V. Barragán-Longoria, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, David Gómez-Almaguer
{"title":"Corrigendum to “Outpatient ATG-free hematopoietic transplantation for severe aplastic anemia in limited-resource environments offers excellent results: Data from a single LATAM center” [Blood Cells, Mol. Dis. 109 (2024) 102885]","authors":"José Carlos Jaime-Pérez,&nbsp;Mariana González-Treviño,&nbsp;Andrés Gómez-De León,&nbsp;Miguel A. Campos-Bocardo,&nbsp;Renata V. Barragán-Longoria,&nbsp;Olga Graciela Cantú-Rodríguez,&nbsp;César Homero Gutiérrez-Aguirre,&nbsp;David Gómez-Almaguer","doi":"10.1016/j.bcmd.2024.102886","DOIUrl":"10.1016/j.bcmd.2024.102886","url":null,"abstract":"","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"110 ","pages":"Article 102886"},"PeriodicalIF":2.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1079979624000640/pdfft?md5=52e69c13f2e3990cdf5b98e200a3ecce&pid=1-s2.0-S1079979624000640-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outpatient ATG-free hematopoietic transplantation for aplastic anemia in limited-resource environments offers excellent results: Data from a single LATAM center 在资源有限的环境中,门诊无ATG造血移植治疗再生障碍性贫血效果极佳:来自拉丁美洲和加勒比海地区一家中心的数据
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-08-20 DOI: 10.1016/j.bcmd.2024.102885
José Carlos Jaime-Pérez, Mariana González-Treviño, Andrés Gómez-De León, Miguel A. Campos-Bocardo, Renata V. Barragán-Longoria, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, David Gómez-Almaguer

Objective

To document the results of outpatient hematopoietic stem cell transplantation (HSCT) from the peripheral blood (PB) of sibling donors without anti-thymocyte globulin (ATG) in the conditioning regimen.

Material and methods

Patients from a low-income population with severe AA who received a PB, unmanipulated sibling HLA-identical HSCT between 2000 and 2020 at a single institution were studied. Survival was the primary outcome.

Results

Forty-one transplants were performed. Time between diagnosis and transplant was five months (1–104). Median age was 37 (range, 4–61) years; 25 (61 %) recipients were males and 32 (78 %) had treatment failure, 9 (22 %) have not received treatment. ATG was administered in 5 (12.2 %) cases; the graft source was PB in 38 (92.7 %) transplants. Twenty-six (63.4 %) transplants were carried out in the outpatient setting. Infections developed in 14 (34.1 %) patients. Primary graft failure (GF) occurred in 3 (7.3 %) patients. The 15-year OS was 81 %, EFS was 77.4 %. Patients with high pre-HSCT transfusion burden had lower OS (p = 0.035) and EFS (p = 0.026). Previous treatment failure and age were not associated with lower OS (p = 0.115, p = 0.069) or EFS (p = 0.088, p = 0.5, respectively).

Conclusions

HLA-identical T-cell replete outpatient HSCT from the PB of sibling donors for AA patients using ATG-free conditioning offers excellent long-term survival.

材料与方法研究了2000年至2020年间在一家医疗机构接受外周血(PB)、无人工配型的同胞HLA相同造血干细胞移植的低收入重症AA患者。结果共进行了 41 例移植。从诊断到移植的时间为5个月(1-104)。中位年龄为 37 岁(4-61 岁);25 例(61%)受者为男性,32 例(78%)治疗失败,9 例(22%)未接受治疗。5例(12.2%)接受了ATG治疗;38例(92.7%)接受了PB移植。26例(63.4%)移植在门诊进行。14例(34.1%)患者发生了感染。3例(7.3%)患者出现原发性移植失败(GF)。15年的OS为81%,EFS为77.4%。HSCT前输血负担较重的患者OS(p = 0.035)和EFS(p = 0.026)较低。结论使用无ATG调理的AA患者从同胞供者血浆中获得的HLA-同源T细胞门诊造血干细胞移植可提供极佳的长期生存率。
{"title":"Outpatient ATG-free hematopoietic transplantation for aplastic anemia in limited-resource environments offers excellent results: Data from a single LATAM center","authors":"José Carlos Jaime-Pérez,&nbsp;Mariana González-Treviño,&nbsp;Andrés Gómez-De León,&nbsp;Miguel A. Campos-Bocardo,&nbsp;Renata V. Barragán-Longoria,&nbsp;Olga Graciela Cantú-Rodríguez,&nbsp;César Homero Gutiérrez-Aguirre,&nbsp;David Gómez-Almaguer","doi":"10.1016/j.bcmd.2024.102885","DOIUrl":"10.1016/j.bcmd.2024.102885","url":null,"abstract":"<div><h3>Objective</h3><p>To document the results of outpatient hematopoietic stem cell transplantation (HSCT) from the peripheral blood (PB) of sibling donors without anti-thymocyte globulin (ATG) in the conditioning regimen.</p></div><div><h3>Material and methods</h3><p>Patients from a low-income population with severe AA who received a PB, unmanipulated sibling HLA-identical HSCT between 2000 and 2020 at a single institution were studied. Survival was the primary outcome.</p></div><div><h3>Results</h3><p>Forty-one transplants were performed. Time between diagnosis and transplant was five months (1–104). Median age was 37 (range, 4–61) years; 25 (61 %) recipients were males and 32 (78 %) had treatment failure, 9 (22 %) have not received treatment. ATG was administered in 5 (12.2 %) cases; the graft source was PB in 38 (92.7 %) transplants. Twenty-six (63.4 %) transplants were carried out in the outpatient setting. Infections developed in 14 (34.1 %) patients. Primary graft failure (GF) occurred in 3 (7.3 %) patients. The 15-year OS was 81 %, EFS was 77.4 %. Patients with high pre-HSCT transfusion burden had lower OS (<em>p</em> = 0.035) and EFS (<em>p</em> = 0.026). Previous treatment failure and age were not associated with lower OS (<em>p</em> = 0.115, <em>p</em> = 0.069) or EFS (<em>p</em> = 0.088, <em>p</em> = 0.5, respectively).</p></div><div><h3>Conclusions</h3><p>HLA-identical T-cell replete outpatient HSCT from the PB of sibling donors for AA patients using ATG-free conditioning offers excellent long-term survival.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"109 ","pages":"Article 102885"},"PeriodicalIF":2.1,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142049734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Red cell distribution width as a bellwether of prognosis 红细胞分布宽度是预后的风向标
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.bcmd.2024.102884
Marshall A. Lichtman

The red cell distribution width (RDW) is a standard variable reported in the complete blood count. It has been found to have a consistent relationship to life expectancy in older individuals, prognosis in patients with cardiovascular disease, outcome in those with hematological and non-hematological neoplasms and in a variety of medical circumstances such as non-cardiovascular or cancer related critical illness and postoperative outcome from various procedures. This report reviews some of the key medical publications establishing these relationships with RDW. The precise pathobiological processes that explain the predictive value of the RDW in this wide array of circumstances or why an alteration in erythropoiesis (exaggerated red cell size variation) occurs is uncertain. The possible role of inflammation has been one hypothesis considered, but not established.

红细胞分布宽度(RDW)是全血细胞计数中的一个标准变量。研究发现,红细胞分布宽度与老年人的预期寿命、心血管疾病患者的预后、血液肿瘤和非血液肿瘤患者的预后以及各种医疗情况(如非心血管疾病或癌症相关的危重病人以及各种手术的术后预后)有着一致的关系。本报告回顾了与 RDW 建立这些关系的一些重要医学出版物。目前还不确定在这些不同情况下 RDW 预测价值的确切病理生物学过程,也不确定为什么会发生红细胞生成的改变(红细胞大小的夸张变化)。炎症可能起的作用是一种假设,但并未得到证实。
{"title":"Red cell distribution width as a bellwether of prognosis","authors":"Marshall A. Lichtman","doi":"10.1016/j.bcmd.2024.102884","DOIUrl":"10.1016/j.bcmd.2024.102884","url":null,"abstract":"<div><p>The red cell distribution width (RDW) is a standard variable reported in the complete blood count. It has been found to have a consistent relationship to life expectancy in older individuals, prognosis in patients with cardiovascular disease, outcome in those with hematological and non-hematological neoplasms and in a variety of medical circumstances such as non-cardiovascular or cancer related critical illness and postoperative outcome from various procedures. This report reviews some of the key medical publications establishing these relationships with RDW. The precise pathobiological processes that explain the predictive value of the RDW in this wide array of circumstances or why an alteration in erythropoiesis (exaggerated red cell size variation) occurs is uncertain. The possible role of inflammation has been one hypothesis considered, but not established.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"109 ","pages":"Article 102884"},"PeriodicalIF":2.1,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics, laboratory features and genetic profile of hemoglobin E (HBB:c.79 G > A)/β (nucleotide -28 A > G) (HBB:c.-78 A > G) -thalassemia subjects identified from community- and hospital-recruited cohorts 从社区和医院招募的队列中确定的血红蛋白 E (HBB:c.79 G > A)/β (核苷酸 -28 A > G) (HBB:c.-78 A > G) - 地中海贫血症受试者的临床特征、实验室特征和遗传特征
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-08-08 DOI: 10.1016/j.bcmd.2024.102883
Piyatida Chumnumsiriwath, Prissana Charoenporn, Sawichayaporn Jermnim, Pawanrat Suannum, Monthira Samaisombat, Akamon Tapprom, Rawisut Deoisares, Peerapon Wong

Despite several existing laboratory-based studies of hemoglobin (Hb) E (HBB:c.79 G > A)/ β (nucleotide (NT) -28 A > G) (HBB:c.-78 A > G) -thalassemia, no reports have ever provided clinical severity information as well as dependency of blood transfusion. Previously, a comparative study of community- and hospital-recruited Hb E/β-thalassemia subjects was conducted in the lower northern Thailand between June 2020 and December 2021. A mobile medical team visited each community hospital on-site, collecting clinical severity parameters, and conducting Hb and DNA analyses. The control included Hb E/β-thalassemia patients undergoing transfusions. Subgroup study of adult Hb E/β (NT -28 A > G) -thalassemia subjects was subsequently conducted. Additional pediatric individuals were recruited from prenatal diagnosis databases. Twenty adult and nine pediatric subjects were enrolled; all were classified as having mild disease severity. Twenty-two individuals (75.9 %) were asymptomatic. Six adults (20.7 %) required blood transfusion. The mean Hb level of subjects without transfusion (23 [79.3 %]) was 10.77 ± 1.10 g/dL. Hb analysis revealed a distinct EFA pattern with low Hb F fraction. The positive impact of genetic modifiers could not be statistically demonstrated except rs7482144-XmnI. These findings could provide essential information for parents carrying fetuses with Hb E/β (NT -28 A > G) -thalassemia.

尽管现有几项关于血红蛋白(Hb)E(HBB:c.79 G > A)/β(核苷酸(NT)-28 A > G)(HBB:c.-78 A > G)地中海贫血症的实验室研究,但从未有报告提供临床严重程度信息以及输血依赖性。此前,一项针对社区和医院招募的 Hb E/β 地中海贫血症受试者的比较研究于 2020 年 6 月至 2021 年 12 月在泰国北部下游地区进行。一支流动医疗队到各社区医院进行现场访问,收集临床严重程度参数,并进行血红蛋白和 DNA 分析。对照组包括接受输血的 Hb E/β 地中海贫血患者。随后对成年 Hb E/β (NT -28 A > G)地中海贫血患者进行了分组研究。此外,还从产前诊断数据库中招募了其他儿童受试者。共招募了 20 名成人受试者和 9 名儿童受试者;所有受试者均被归类为病情严重程度较轻的患者。22人(75.9%)无症状。六名成人(20.7%)需要输血。没有输血的受试者(23 人 [79.3%])的平均血红蛋白水平为 10.77 ± 1.10 g/dL。血红蛋白分析显示出明显的 EFA 模式,血红蛋白 F 分数较低。除 rs7482144-XmnI 外,遗传修饰因子的积极影响在统计学上无法证实。这些发现可为怀有 Hb E/β (NT -28 A > G)-地中海贫血胎儿的父母提供重要信息。
{"title":"Clinical characteristics, laboratory features and genetic profile of hemoglobin E (HBB:c.79 G > A)/β (nucleotide -28 A > G) (HBB:c.-78 A > G) -thalassemia subjects identified from community- and hospital-recruited cohorts","authors":"Piyatida Chumnumsiriwath,&nbsp;Prissana Charoenporn,&nbsp;Sawichayaporn Jermnim,&nbsp;Pawanrat Suannum,&nbsp;Monthira Samaisombat,&nbsp;Akamon Tapprom,&nbsp;Rawisut Deoisares,&nbsp;Peerapon Wong","doi":"10.1016/j.bcmd.2024.102883","DOIUrl":"10.1016/j.bcmd.2024.102883","url":null,"abstract":"<div><p>Despite several existing laboratory-based studies of hemoglobin (Hb) E (HBB:c.79 G &gt; A)/ β (nucleotide (NT) -28 A &gt; G) (HBB:c.-78 A &gt; G) -thalassemia, no reports have ever provided clinical severity information as well as dependency of blood transfusion. Previously, a comparative study of community- and hospital-recruited Hb E/β-thalassemia subjects was conducted in the lower northern Thailand between June 2020 and December 2021. A mobile medical team visited each community hospital on-site, collecting clinical severity parameters, and conducting Hb and DNA analyses. The control included Hb E/β-thalassemia patients undergoing transfusions. Subgroup study of adult Hb E/β (NT -28 A &gt; G) -thalassemia subjects was subsequently conducted. Additional pediatric individuals were recruited from prenatal diagnosis databases. Twenty adult and nine pediatric subjects were enrolled; all were classified as having mild disease severity. Twenty-two individuals (75.9 %) were asymptomatic. Six adults (20.7 %) required blood transfusion. The mean Hb level of subjects without transfusion (23 [79.3 %]) was 10.77 ± 1.10 g/dL. Hb analysis revealed a distinct EFA pattern with low Hb F fraction. The positive impact of genetic modifiers could not be statistically demonstrated except rs7482144-<em>Xmn</em>I. These findings could provide essential information for parents carrying fetuses with Hb E/β (NT -28 A &gt; G) -thalassemia.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"109 ","pages":"Article 102883"},"PeriodicalIF":2.1,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141997700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erythrocyte deformability correlates with systemic inflammation 红细胞变形性与全身炎症相关
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-08-02 DOI: 10.1016/j.bcmd.2024.102881
Carmen Jacob , Lakeesha Piyasundara , Maria Bonello , Michael Nathan , Stefania Kaninia , Aravinthan Varatharaj , Noémi Roy , Ian Galea

Recent evidence suggests that systemic conditions, particularly those associated with inflammation, can affect erythrocyte deformability in the absence of haematological conditions. In this exploratory study, we investigated the relationship between systemic inflammatory status and erythrocyte deformability (using osmotic gradient ektacytometry) in a heterogenous study population consisting of individuals with no medical concerns, chronic conditions, and acute illness, providing a wide range of systemic inflammation severity.

22 participants were included in a prospective observational study. Maximum Elongation Index (EImax) in ektacytometry served as the readout for erythrocyte deformability. Inflammatory status was assessed using C-reactive protein (CRP) and self-reported symptoms associated with inflammatory activation (Sickness Questionnaire Scores, SicknessQ).

In a univariate linear regression, both CRP and SicknessQ scores significantly predicted EImax (CRP: F(1,20) = 7.751, p < 0.05 (0.011), R2 = 0.279; SicknessQ: F(1,18) = 4.831, p < 0.05 (0.041), R2 = 0.212). Sensitivity analyses with multivariable linear regression correcting for age showed concordant findings.

Results suggest a linear relationship between erythrocyte deformability and biochemical and clinical markers of systemic inflammation. Replication of findings in a larger study, and mechanisms and clinical consequences need further in investigation.

最近的证据表明,全身性疾病,尤其是与炎症相关的疾病,会在没有血液病的情况下影响红细胞的变形性。在这项探索性研究中,我们调查了系统性炎症状态与红细胞变形性之间的关系(使用渗透梯度红细胞计数法),研究对象是由无病症、慢性病和急性病患者组成的异质性研究人群,提供了广泛的系统性炎症严重程度。红细胞最大伸长指数(EImax)是红细胞变形性的读数。炎症状态通过 C 反应蛋白(CRP)和与炎症激活相关的自我报告症状(疾病问卷评分,SicknessQ)进行评估。在单变量线性回归中,CRP 和 SicknessQ 评分均可显著预测 EImax(CRP:F(1,20) = 7.751,p < 0.05 (0.011),R2 = 0.279;SicknessQ:F(1,18) = 4.831,p < 0.05 (0.041),R2 = 0.212)。结果表明,红细胞变形性与全身炎症的生化和临床指标之间存在线性关系。研究结果表明,红细胞变形性与全身炎症的生化和临床指标之间存在线性关系。
{"title":"Erythrocyte deformability correlates with systemic inflammation","authors":"Carmen Jacob ,&nbsp;Lakeesha Piyasundara ,&nbsp;Maria Bonello ,&nbsp;Michael Nathan ,&nbsp;Stefania Kaninia ,&nbsp;Aravinthan Varatharaj ,&nbsp;Noémi Roy ,&nbsp;Ian Galea","doi":"10.1016/j.bcmd.2024.102881","DOIUrl":"10.1016/j.bcmd.2024.102881","url":null,"abstract":"<div><p>Recent evidence suggests that systemic conditions, particularly those associated with inflammation, can affect erythrocyte deformability in the absence of haematological conditions. In this exploratory study, we investigated the relationship between systemic inflammatory status and erythrocyte deformability (using osmotic gradient ektacytometry) in a heterogenous study population consisting of individuals with no medical concerns, chronic conditions, and acute illness, providing a wide range of systemic inflammation severity.</p><p>22 participants were included in a prospective observational study. Maximum Elongation Index (EI<sub>max</sub>) in ektacytometry served as the readout for erythrocyte deformability. Inflammatory status was assessed using C-reactive protein (CRP) and self-reported symptoms associated with inflammatory activation (Sickness Questionnaire Scores, SicknessQ).</p><p>In a univariate linear regression, both CRP and SicknessQ scores significantly predicted EI<sub>max</sub> (CRP: F(1,20) = 7.751, <em>p</em> &lt; 0.05 (0.011), R<sup>2</sup> = 0.279; SicknessQ: F(1,18) = 4.831, p &lt; 0.05 (0.041), R<sup>2</sup> = 0.212). Sensitivity analyses with multivariable linear regression correcting for age showed concordant findings.</p><p>Results suggest a linear relationship between erythrocyte deformability and biochemical and clinical markers of systemic inflammation. Replication of findings in a larger study, and mechanisms and clinical consequences need further in investigation.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"109 ","pages":"Article 102881"},"PeriodicalIF":2.1,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1079979624000597/pdfft?md5=f23be722aa973fc8705021ee36b6de01&pid=1-s2.0-S1079979624000597-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141991059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical utility of relative telomere length analysis in pediatric bone marrow failure 相对端粒长度分析在小儿骨髓衰竭中的临床应用。
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-07-31 DOI: 10.1016/j.bcmd.2024.102882
Shilpa Amatya , Prateek Bhatia , Sudhanshi Raina , Sreejesh Sreedharanunni , Minu Singh , Emine Rahman , M.V. Archana , Amita Trehan

Introduction

Telomere length related studies are limited in pediatric marrow failure cases due to difficulty in establishing population specific age related normograms. Moreover, there is paucity of data related to clinical relevance of telomere length in idiopathic aplastic anemia (IAA) and non telomere biology inherited bone marrow failure syndrome (IBMFS) cases. Methodology: Hence, in current study we investigated Relative telomere length (RTL) by RQ-PCR in 83 samples as: healthy controls (n = 44), IAA (n = 15) and IBMFS (n = 24). In addition, we performed chromosomal breakage studies and targeted NGS to screen for pathogenic variants. Results & Conclusion: Median RTL was significantly different between control vs. IBMFS (p-0.002), IAA vs. IBMFS (p-0.0075) and DC vs. non-DC IBMFS (p-0.011) but not between control vs. IAA (p-0.46). RTL analysis had clinical utility in differentiating BMF cases as 75 % (9/12) of DC had short/very short telomeres compared to only 17 % (2/12) of non-DC IBMFS, 7 % (1/15) of IAA and 7 % (3/44) of controls (p < 0.001).

导言:由于难以确定特定人群的年龄相关标准图,与端粒长度相关的研究在小儿骨髓衰竭病例中非常有限。此外,关于特发性再生障碍性贫血(IAA)和非端粒生物学遗传性骨髓衰竭综合征(IBMFS)病例中端粒长度的临床相关性的数据也很少。方法:因此,在当前的研究中,我们通过RQ-PCR对83个样本中的相对端粒长度(RTL)进行了调查,这些样本包括:健康对照(n = 44)、IAA(n = 15)和IBMFS(n = 24)。此外,我们还进行了染色体断裂研究和靶向 NGS,以筛查致病变体:对照组与 IBMFS(p-0.002)、IAA 与 IBMFS(p-0.0075)、DC 与非 DC IBMFS(p-0.011)之间的中位 RTL 有明显差异,但对照组与 IAA 之间没有差异(p-0.46)。RTL分析在区分BMF病例方面具有临床实用性,因为75%(9/12)的DC具有短端粒/极短端粒,而非DC IBMFS中只有17%(2/12)、IAA中7%(1/15)和对照组中7%(3/44)具有短端粒/极短端粒。
{"title":"Clinical utility of relative telomere length analysis in pediatric bone marrow failure","authors":"Shilpa Amatya ,&nbsp;Prateek Bhatia ,&nbsp;Sudhanshi Raina ,&nbsp;Sreejesh Sreedharanunni ,&nbsp;Minu Singh ,&nbsp;Emine Rahman ,&nbsp;M.V. Archana ,&nbsp;Amita Trehan","doi":"10.1016/j.bcmd.2024.102882","DOIUrl":"10.1016/j.bcmd.2024.102882","url":null,"abstract":"<div><h3>Introduction</h3><p>Telomere length related studies are limited in pediatric marrow failure cases due to difficulty in establishing population specific age related normograms. Moreover, there is paucity of data related to clinical relevance of telomere length in idiopathic aplastic anemia (IAA) and non telomere biology inherited bone marrow failure syndrome (IBMFS) cases. Methodology: Hence, in current study we investigated Relative telomere length (RTL) by RQ-PCR in 83 samples as: healthy controls (<em>n</em> = 44), IAA (<em>n</em> = 15) and IBMFS (<em>n</em> = 24). In addition, we performed chromosomal breakage studies and targeted NGS to screen for pathogenic variants. Results &amp; Conclusion: Median RTL was significantly different between control vs. IBMFS (<em>p</em>-0.002), IAA vs. IBMFS (<em>p</em>-0.0075) and DC vs. non-DC IBMFS (<em>p</em>-0.011) but not between control vs. IAA (<em>p</em>-0.46). RTL analysis had clinical utility in differentiating BMF cases as 75 % (9/12) of DC had short/very short telomeres compared to only 17 % (2/12) of non-DC IBMFS, 7 % (1/15) of IAA and 7 % (3/44) of controls (<em>p</em> &lt; 0.001).</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"109 ","pages":"Article 102882"},"PeriodicalIF":2.1,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 50th anniversary of Blood Cells, Molecules and Diseases, 1975–2024 血细胞、分子和疾病》50 周年纪念,1975-2024 年
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-07-19 DOI: 10.1016/j.bcmd.2024.102854
Marshall A. Lichtman
<div><p>The journal <em>Blood Cells</em> was initiated in 1975 by Marcel Bessis, a French hematologist and cell biologist, as a vehicle for the publication of papers and discussions presented at an international blood club meeting he convened at L' Institut de Pathologie Cellulaire on the campus of Hôpital Bicétre in Kremlin Bicétre, France, a commune on the southern border of Paris. The group met at the Institute for the first time in October 1972. After the first meeting, Bessis published the articles describing the presentations in the <em>Nouvelle Revue d'Hématologie Française</em>, France's principal journal for articles on the science and practice of hematology of which he was the editor. The refusal of the <em>Nouvelle Revue d'Hématologie Française</em> to continue publishing the papers from the meeting of the blood club in English prompted Bessis to start a new journal, <em>Blood Cells</em>, in 1975. <em>Blood Cells</em>, also, began to accept individual submitted papers unrelated to the blood club meeting and, thus, it evolved into a standard journal. A decade later, when Bessis became ill, he asked Brian Bull, a hematopathologist and professor at Loma Linda University School of Medicine in California to assume the position as the second editor-in-chief. He and Bessis had become scientific collaborators and good friends in the preceding years. In 1995, Ernest Beutler, Chair of Molecular and Experimental Medicine at Scripps Research Institute, assumed the editor-in-chief position and transformed the <em>Journal</em> by making three consequential changes. He expanded its title to <em>Blood Cells, Molecules and Diseases</em>, converted its editorial board to past presidents of the American Society of Hematology plus a few additional experimental hematologists of note, a few from abroad, and he converted the <em>Journal</em> to a digital format, hosted on the Scripps Research Institute server. The <em>Journal</em> was the first published solely in a digital format. It, subsequently, was bought by Academic Press, then Harcourt and, then, by Elsevier. The next three editors-in-chief were (i) Marshall A. Lichtman, then Professor of Medicine (Hematology) and of Biochemistry and Biophysics and former Dean of the School of Medicine and Dentistry at the University of Rochester Medical Center, editor from 2000 to 2013, (ii) Mohandas Narla, then Vice President for Research and Director of The Laboratory of Red Cell Physiology at the New York Blood Center, editor from 2014 to 2021 and (iii) Lionel Blanc, Professor of Molecular Medicine and Pediatrics, Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research and the Les Nelkin Professor of Pediatric Oncology Donald and Barbara Zucker School of Medicine at Hofstra-Northwell from 2022 to the present. Although the <em>Journal</em> publishes papers on any aspect of hematology, it has developed a focus on disorders of r
1975年,法国血液学和细胞生物学家马塞尔-贝西斯(Marcel Bessis)在法国巴黎南部边境的克姆林比塞特尔市比塞特尔医院(Hôpital Bicétre)校园内的细胞病理研究所(L' Institut de Pathologie Cellulaire)召开了一次国际血液俱乐部会议,会上发表的论文和进行的讨论成为《血细胞》杂志的载体。该小组于 1972 年 10 月在研究所举行了第一次会议。第一次会议后,贝西斯在《法国血液学新评论》(Nouvelle Revue d'Hématologie Française)上发表了介绍会议情况的文章。由于《法国新血液学杂志》拒绝继续用英文发表血液俱乐部会议的论文,贝西斯于 1975 年创办了一份新杂志《血细胞》。血细胞》也开始接受个人提交的与血液俱乐部会议无关的论文,并由此发展成为一份标准期刊。十年后,贝西斯病逝,他邀请加州洛马琳达大学医学院教授、血液病理学家布莱恩-布尔担任第二任主编。此前几年,他和贝西斯已成为科研合作者和好朋友。1995 年,斯克里普斯研究所分子与实验医学主席欧内斯特-比尤特勒就任主编一职,并对期刊进行了三项重大改革。他将期刊名称改为《血细胞、分子和疾病》,将编委会成员改为美国血液学会前任主席以及其他几位著名的实验血液学家,其中有几位来自国外,并将期刊转换为数字格式,托管在斯克里普斯研究所的服务器上。该期刊是第一本完全以数字格式出版的期刊。随后,它先后被学术出版社、哈科特出版社和爱思唯尔出版社收购。接下来的三位主编分别是:(i) Marshall A.Lichtman,时任罗切斯特大学医学中心医学(血液学)和生物化学与生物物理学教授,医学与牙科学院前院长,2000 年至 2013 年的编辑;(ii) Mohandas Narla,时任纽约血液中心研究副总裁兼红细胞生理学实验室主任,2014 年至 2021 年的编辑;以及(iii) R. M. B. M. M. M. M、2014年至2021年担任编辑,(iii) 2022年至今担任编辑的是Lionel Blanc,他是费恩斯坦医学研究所分子医学研究所自身免疫、肌肉骨骼和造血疾病中心的分子医学和儿科教授,以及霍夫斯特拉-诺斯韦尔大学唐纳德和芭芭拉-扎克医学院儿科肿瘤学Les Nelkin教授。尽管该杂志发表的论文涉及血液学的方方面面,但它已将重点放在红细胞、红细胞生成和造血功能紊乱方面。2024 年 10 月,《血液学杂志》将迎来创刊 50 周年。
{"title":"The 50th anniversary of Blood Cells, Molecules and Diseases, 1975–2024","authors":"Marshall A. Lichtman","doi":"10.1016/j.bcmd.2024.102854","DOIUrl":"10.1016/j.bcmd.2024.102854","url":null,"abstract":"&lt;div&gt;&lt;p&gt;The journal &lt;em&gt;Blood Cells&lt;/em&gt; was initiated in 1975 by Marcel Bessis, a French hematologist and cell biologist, as a vehicle for the publication of papers and discussions presented at an international blood club meeting he convened at L' Institut de Pathologie Cellulaire on the campus of Hôpital Bicétre in Kremlin Bicétre, France, a commune on the southern border of Paris. The group met at the Institute for the first time in October 1972. After the first meeting, Bessis published the articles describing the presentations in the &lt;em&gt;Nouvelle Revue d'Hématologie Française&lt;/em&gt;, France's principal journal for articles on the science and practice of hematology of which he was the editor. The refusal of the &lt;em&gt;Nouvelle Revue d'Hématologie Française&lt;/em&gt; to continue publishing the papers from the meeting of the blood club in English prompted Bessis to start a new journal, &lt;em&gt;Blood Cells&lt;/em&gt;, in 1975. &lt;em&gt;Blood Cells&lt;/em&gt;, also, began to accept individual submitted papers unrelated to the blood club meeting and, thus, it evolved into a standard journal. A decade later, when Bessis became ill, he asked Brian Bull, a hematopathologist and professor at Loma Linda University School of Medicine in California to assume the position as the second editor-in-chief. He and Bessis had become scientific collaborators and good friends in the preceding years. In 1995, Ernest Beutler, Chair of Molecular and Experimental Medicine at Scripps Research Institute, assumed the editor-in-chief position and transformed the &lt;em&gt;Journal&lt;/em&gt; by making three consequential changes. He expanded its title to &lt;em&gt;Blood Cells, Molecules and Diseases&lt;/em&gt;, converted its editorial board to past presidents of the American Society of Hematology plus a few additional experimental hematologists of note, a few from abroad, and he converted the &lt;em&gt;Journal&lt;/em&gt; to a digital format, hosted on the Scripps Research Institute server. The &lt;em&gt;Journal&lt;/em&gt; was the first published solely in a digital format. It, subsequently, was bought by Academic Press, then Harcourt and, then, by Elsevier. The next three editors-in-chief were (i) Marshall A. Lichtman, then Professor of Medicine (Hematology) and of Biochemistry and Biophysics and former Dean of the School of Medicine and Dentistry at the University of Rochester Medical Center, editor from 2000 to 2013, (ii) Mohandas Narla, then Vice President for Research and Director of The Laboratory of Red Cell Physiology at the New York Blood Center, editor from 2014 to 2021 and (iii) Lionel Blanc, Professor of Molecular Medicine and Pediatrics, Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research and the Les Nelkin Professor of Pediatric Oncology Donald and Barbara Zucker School of Medicine at Hofstra-Northwell from 2022 to the present. Although the &lt;em&gt;Journal&lt;/em&gt; publishes papers on any aspect of hematology, it has developed a focus on disorders of r","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"108 ","pages":"Article 102854"},"PeriodicalIF":2.1,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141729243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sickle cell disease in Indian tribal population: Findings of a multi-centre Indian SCD registry 印度部落人口中的镰状细胞病:印度镰状细胞病多中心登记结果
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-07-14 DOI: 10.1016/j.bcmd.2024.102873
Yogita Sharma , Deepa Bhat , Parikipandla Sridevi , Shaily B. Surti , Manoranjan Ranjit , Jatin Sarmah , Godi Sudhakar , Bontha V. Babu

Background

Sickle cell disease (SCD) registries provide crucial real-world data on demographics, epidemiology, healthcare, patient outcomes, and treatment efficacy. This paper presents findings from the Indian SCD Registry (ISCDR) on clinical manifestations, crisis episodes, disease management, and healthcare utilization in patients with SCD from 12 primary health centres (PHCs) in six tribal districts of India.

Methods

The ISCDR was introduced along with a three-tier screening process. Its Android-based application incorporates two electronic case report forms for patient data collection over one year. This paper presents a year's data from the ISCDR's 324 patients with SCD.

Results

Patients with SCD, aged one to 65 years, exhibited varied clinical manifestations. Most patients (85.2 %) were unaware of their SCD status before enrolling in ISCDR. Moderate to severe anaemia was prevalent (66.05 % and 30.56 %, respectively). Pain was a common complaint (80.86 %; CI: 76.17–85.00), while symptoms of stroke included sudden severe headaches (34.57 %; CI: 29.40–40.02). Common splenic sequestration symptoms included stomach pain (42.90 %; CI: 37.44–48.49) and abdominal tenderness (13.27 %; CI: 9.77–17.46), as a sign. Healthcare utilization was high, with 96.30 % receiving treatment and 83.64 % consuming hydroxyurea. Hospitalization occurred for 38.27 % (CI: 32.95–43.81), and 12.04 % (CI: 8.70–16.09) had blood transfusion during last year.

Conclusions

ISCDR serves as a dynamic digital database on SCD epidemiology, clinical aspects, treatment and healthcare utilization. Notably, many patients lacked prior awareness of their SCD status, underscoring the need for improved awareness and care management. Integrating the registry into the national programme can streamline treatment implementation, prioritize management approaches, and optimize individual benefits.

背景镰状细胞病 (SCD) 登记提供了有关人口统计学、流行病学、医疗保健、患者预后和治疗效果的重要真实数据。本文介绍了印度镰状细胞病登记处(ISCDR)对印度六个部落地区 12 个初级保健中心(PHC)的镰状细胞病患者的临床表现、危机发作、疾病管理和医疗保健利用情况的调查结果。其基于安卓系统的应用程序包含两份电子病例报告表,用于收集一年来的患者数据。结果SCD患者的年龄从1岁到65岁不等,临床表现各不相同。大多数患者(85.2%)在加入 ISCDR 之前并不知道自己患有 SCD。患者普遍患有中度至重度贫血(分别占 66.05% 和 30.56%)。疼痛是常见的主诉(80.86%;CI:76.17-85.00),而中风症状包括突发剧烈头痛(34.57%;CI:29.40-40.02)。常见的脾疝症状包括胃痛(42.90%;CI:37.44-48.49)和腹部压痛(13.27%;CI:9.77-17.46)。医疗利用率很高,96.30%的患者接受了治疗,83.64%的患者服用了羟基脲。38.27% (CI: 32.95-43.81)的患者住院治疗,12.04% (CI: 8.70-16.09)的患者去年输过血。值得注意的是,许多患者事先并不了解自己的 SCD 状况,这说明需要提高对 SCD 的认识并加强护理管理。将登记册纳入国家计划可简化治疗实施、确定管理方法的优先次序并优化个人利益。
{"title":"Sickle cell disease in Indian tribal population: Findings of a multi-centre Indian SCD registry","authors":"Yogita Sharma ,&nbsp;Deepa Bhat ,&nbsp;Parikipandla Sridevi ,&nbsp;Shaily B. Surti ,&nbsp;Manoranjan Ranjit ,&nbsp;Jatin Sarmah ,&nbsp;Godi Sudhakar ,&nbsp;Bontha V. Babu","doi":"10.1016/j.bcmd.2024.102873","DOIUrl":"10.1016/j.bcmd.2024.102873","url":null,"abstract":"<div><h3>Background</h3><p>Sickle cell disease (SCD) registries provide crucial real-world data on demographics, epidemiology, healthcare, patient outcomes, and treatment efficacy. This paper presents findings from the Indian SCD Registry (ISCDR) on clinical manifestations, crisis episodes, disease management, and healthcare utilization in patients with SCD from 12 primary health centres (PHCs) in six tribal districts of India.</p></div><div><h3>Methods</h3><p>The ISCDR was introduced along with a three-tier screening process. Its Android-based application incorporates two electronic case report forms for patient data collection over one year. This paper presents a year's data from the ISCDR's 324 patients with SCD.</p></div><div><h3>Results</h3><p>Patients with SCD, aged one to 65 years, exhibited varied clinical manifestations. Most patients (85.2 %) were unaware of their SCD status before enrolling in ISCDR. Moderate to severe anaemia was prevalent (66.05 % and 30.56 %, respectively). Pain was a common complaint (80.86 %; CI: 76.17–85.00), while symptoms of stroke included sudden severe headaches (34.57 %; CI: 29.40–40.02). Common splenic sequestration symptoms included stomach pain (42.90 %; CI: 37.44–48.49) and abdominal tenderness (13.27 %; CI: 9.77–17.46), as a sign. Healthcare utilization was high, with 96.30 % receiving treatment and 83.64 % consuming hydroxyurea. Hospitalization occurred for 38.27 % (CI: 32.95–43.81), and 12.04 % (CI: 8.70–16.09) had blood transfusion during last year.</p></div><div><h3>Conclusions</h3><p>ISCDR serves as a dynamic digital database on SCD epidemiology, clinical aspects, treatment and healthcare utilization. Notably, many patients lacked prior awareness of their SCD status, underscoring the need for improved awareness and care management. Integrating the registry into the national programme can streamline treatment implementation, prioritize management approaches, and optimize individual benefits.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"109 ","pages":"Article 102873"},"PeriodicalIF":2.1,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141637396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerated phase development in a late-onset adolescent Chediak-Higashi syndrome patient caused by compound novel LYST mutations in the setting of SARS-CoV-2 infection 在感染 SARS-CoV-2 的情况下,由新型 LYST 复合突变引起的晚发性青少年切迪克-希加希综合征患者的病情加速发展
IF 2.1 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-07-11 DOI: 10.1016/j.bcmd.2024.102874
Ping Guo , Xi Wu , Mingkang Yang, Yilun Xue, Jiakuan Zhou, Zhixi Huang, Wenman Wu, Jianbiao Wang

Chediak-Higashi syndrome (CHS) is a rare autosomal recessive genetic disorder characterized by severe immunodeficiency, albinism and coagulation deficiency. Mostly diagnosed in early childhood, this devastating condition is associated with lysosomal abnormalities attributed to the absence or impaired function of lysosomal trafficking regulator caused by mutations in the CHS1/LYST gene. In current study, we report a case of late-onset CHS caused by two novel compound heterozygous CHS1/LYST mutations: c.8407C > T, leading to early termination of translation at residue Gln2803 (p. Gln2803Ter), and a small deletion c. 4020_4031del, resulting in an in-frame deletion of three amino acid residues (p. Asp1343_Val1346del). Both variants retain a large part of the CHS/LYST protein, particularly p. Asp1343_Val1346del, which preserves critical functional BEACH and WD40 domains in the C terminal, potentially maintaining residual activity and alleviating patient symptoms. The timeline of SARS-CoV-2 infection and rapid symptom progression suggests that the viral infection may have trigger the accelerated phase development leading to a poor prognosis.

切迪克-希加希综合征(CHS)是一种罕见的常染色体隐性遗传疾病,以严重的免疫缺陷、白化病和凝血功能障碍为特征。这种毁灭性疾病多在儿童早期诊断,与溶酶体异常有关,原因是 CHS1/LYST 基因突变导致溶酶体转运调节因子缺失或功能受损。在本研究中,我们报告了一例由两个新型复合杂合子 CHS1/LYST 突变引起的晚发型 CHS:c.8407C >T,导致残基 Gln2803 翻译提前终止(p. Gln2803Ter),以及一个小缺失 c.4020_4031del,导致三个氨基酸残基的框内缺失(p. Asp1343_Val1346del)。这两个变体都保留了 CHS/LYST 蛋白的大部分,尤其是 p. Asp1343_Val1346del,它保留了 C 端关键的 BEACH 和 WD40 功能域,有可能保持残余活性并减轻患者症状。SARS-CoV-2 感染的时间线和症状的快速发展表明,病毒感染可能引发了加速期的发展,导致预后不良。
{"title":"Accelerated phase development in a late-onset adolescent Chediak-Higashi syndrome patient caused by compound novel LYST mutations in the setting of SARS-CoV-2 infection","authors":"Ping Guo ,&nbsp;Xi Wu ,&nbsp;Mingkang Yang,&nbsp;Yilun Xue,&nbsp;Jiakuan Zhou,&nbsp;Zhixi Huang,&nbsp;Wenman Wu,&nbsp;Jianbiao Wang","doi":"10.1016/j.bcmd.2024.102874","DOIUrl":"10.1016/j.bcmd.2024.102874","url":null,"abstract":"<div><p>Chediak-Higashi syndrome (CHS) is a rare autosomal recessive genetic disorder characterized by severe immunodeficiency, albinism and coagulation deficiency. Mostly diagnosed in early childhood, this devastating condition is associated with lysosomal abnormalities attributed to the absence or impaired function of lysosomal trafficking regulator caused by mutations in the <em>CHS1/LYST</em> gene. In current study, we report a case of late-onset CHS caused by two novel compound heterozygous <em>CHS1/LYST</em> mutations: c.8407C &gt; T, leading to early termination of translation at residue Gln2803 (p. Gln2803Ter), and a small deletion c. 4020_4031del, resulting in an in-frame deletion of three amino acid residues (p. Asp1343_Val1346del). Both variants retain a large part of the CHS/LYST protein, particularly p. Asp1343_Val1346del, which preserves critical functional BEACH and WD40 domains in the C terminal, potentially maintaining residual activity and alleviating patient symptoms. The timeline of SARS-CoV-2 infection and rapid symptom progression suggests that the viral infection may have trigger the accelerated phase development leading to a poor prognosis.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"109 ","pages":"Article 102874"},"PeriodicalIF":2.1,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141698963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Blood Cells Molecules and Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1